

**VIVALIS AND CSL LIMITED SIGNED A RESEARCH LICENCE
AND OPTION OF COMMERCIAL LICENCE AGREEMENT
TO MANUFACTURE A THERAPEUTIC PROTEIN WITH THE EBx[®] PLATFORM**

Nantes (France) – October 7th, 2008 – CSL Limited (ASX: CSL) and VIVALIS (NYSE Euronext: VLS) announced today that they have signed a research licence and option for a commercial agreement to assess the EBx[®] platform. The purpose of the agreement is to test the EB66[®] cell line for the development and manufacturing of a therapeutic protein candidate.

CSL Limited is a global specialist biopharmaceutical company that researches, develops, manufactures and markets biotherapies used to treat serious diseases.

“VIVALIS is very happy to enter into this agreement with one of the world leaders in the field of protein biotherapeutics and to participate in CSL Limited’s R&D efforts to evaluate VIVALIS EB66[®] cell line potential to express therapeutic proteins with improved biological activities. With 5 agreements signed within a year in the field of therapeutic proteins, VIVALIS EB66[®] cell line constitutes a new and promising alternative to the classical CHO manufacturing cell line”, said Frank GRIMAUD, VIVALIS CEO.

Terms of the agreement were not disclosed.

Next Vivalis press release:

November 13rd, after Euronext market closing: 3rd quarter sales

About CSL (www.csl.com.au)

The CSL Group has a combined heritage of outstanding contribution to medicine and human health with more than 90 years experience in the development and manufacture of vaccines and plasma protein biotherapies.

With major facilities in Australia, Germany, Switzerland and the US, CSL has over 9000 employees working in 27 countries.

About VIVALIS (www.vivalis.com)

VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. VIVALIS’ expertise and intellectual property are exploited in three main areas:

1. The development and manufacturing of vaccines. VIVALIS offers research and commercial licenses for its EB66® cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of viral vaccines. Vivalis receives up front, milestones and royalties payments on its licensees net sales.
2. The development of production systems for recombinant proteins and monoclonal antibodies. VIVALIS licenses its EB66® cell line for the production of recombinant proteins to biotechnology and pharmaceutical companies. Vivalis receives up front, milestones, and royalties payments on its licensees net sales.
3. The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (hepatitis C).

Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group (1,450 employees), the second largest group worldwide in animal genetic selection. VIVALIS has established numerous partnerships with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Kaketsuken, CSL, Meril and SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES bio-cluster.

Euronext Paris Compartment C - FR0004056851
Reuters: **VLS.PA** – Bloomberg: **VLS FP**

Investor relations:

VIVALIS

Franck Grimaud, C.E.O.

Email: investors@vivalis.com

NewCap

Financial Communication Agency

Steve Grobet / Emmanuel Huynh

Tel.: +33 (0) 1 44 71 94 91

Email: vivalis@newcap.fr